Benzydamine in Managing Chemoradiotherapy-Related Oral Mucositis: A Preventive and Therapeutic Approach

Dr. Victor Castillo[1], Dr. Gabriela Morales[2]
[1]Faculty of Pharmacy, University of Costa Rica, San José, Costa Rica
[2]Department of Pharmaceutical Sciences, University of Panama, Panama City, Panama

Received: 19-03-2025; Revised: 11-04-2025; Accepted: 27-04-2025; Published: 27-05-2025

Abstract

Contemporary pharmacy practice now includes many new tasks, including caring for patients, promoting public health, deciding on medication and working with other health workers. Health professionals rely on pharmacists for their involvement in monitoring drugs, treating chronic illnesses, giving immunizations and watching for side effects. At the same time, pharmacy technicians are now essential members, helping maintain an efficient pharmacy, keep inventory well-managed and prepare medicines correctly. This broadening area of work fits with changes in healthcare that center on making services accessible, safe and focused on results. Also, with electronic prescribing and telepharmacy becoming more common, the way pharmacy professionals function has been transformed. Moving ahead, both pharmacists and pharmacy technicians work to meet new expectations and talents thanks to continual changes in education and laws. In this work, we examine how these experts' roles have shifted in the modern pharmacy environment and highlight the benefits of flexible models, ongoing professional growth and collaborative ways for reaching the best results for patients.

Keywords: ***Benzydamine, Chemoradiotherapy, Oral Mucositis, Inflammation, Supportive Oncology, Mucosal Protection, Radiotherapy Toxicity, Cancer Treatment Side Effects, NSAIDs, Palliative Care.***

1.Introduction

In the field of oncology, challenges caused by treatment complications can lower a patient's quality of life, affect how well they follow their treatment and alter the complete success of therapies. Oral mucositis is one of these problems and affects a big group of patients being treated with chemotherapy and radiotherapy. As a result, people with the condition experience painful inflammation and ulceration inside the mouth and throat which hinder eating, speaking and caring for their teeth. This condition happens through a series of inflammatory reactions when cells are damaged by chemotherapy, resulting in germ contamination and painfully long healing. So far, medical managers have mainly used pain medicines and extra nursing support to treat mucositis, though they have had little effect in avoiding or lessening such episodes. Yet, the success of benzydamine hydrochloride makes it possible to help manage mucositis in advance(1). Many clinical trials have found that benzydamine, a non-steroidal anti-inflammatory drug, shows great effectiveness in treating head and neck cancer patients given radiation therapy. Besides simply helping with inflammation, the drug has analgesic, antibacterial and supportive effects that address several parts of how mucositis occurs. Guides issued by MASCIC/ISOO and other international associations have acknowledged how benzydamine can help prevent mucositis and included recommendations for using it as prescribed. Many studies now prove that benzydamine works well which has resulted in its use in clinics all over the world, but questions remain about the proper doses, ideal patients and new ways benzydamine may be applied. This broad study seeks to find out how benzydamine is used in cancer care, how it works, where it is applied in practice, how safe it is and what its prospects are for managing and avoiding mucositis.

2.Workings of Benzydamine at the Cellular and Dosage Interactions Level

Its unique chemical structure and the many actions it has make benzydamine more effective at preventing mucositis than most other non-steroidal anti-inflammatory drugs. Essentially, benzydamine suppresses the production of the major pro-inflammatory cytokines TNF-α and IL-1β which drive the inflammatory response seen in radiation-induced mucositis. Unlike most NSAIDs that mostly turn off cyclooxygenase enzymes, benzydamine stops the signaling pathway of NF-κB, preventing inflammatory genes from being switched on. Managing inflammation by picking certain pathways maintains the body's ability to heal and recover(2). Since the drug helps build stability in

the cell membranes and lowers vascular permeability, it limits the amount of harm caused by radiation to the oral mucosa. Benzydamine also works as an antioxidant, scavenging reactive oxygen species that might cause extra stress in the body because of radiation therapy.



FIGURE 1 Which anti-inflammatory approach is more effective for mucositis prevention?

The local anesthetic effect of the compound soothes symptoms fast by stopping sodium channels and it also fights many oral infections to help avoid complications in healing mucositis. Because benzydamine is not taken up by the body very much after topical use, it can work on oral tissues for long periods without causing many systemic side effects. Since the drug is most soluble at a pH slightly lower than that found in cells, it can be taken up well by tissues affected by inflammation(3). New research has found that benzydamine influences metalloproteinases, proteins critical for the repairing and reshaping of tissues during wound healing. With this approach, several paths linked to mucositis development are treated together, including the harm to cells, the buildup of inflammation and the final healing.

3.Clinical data and processes for treatment venne

The use of benzydamine to prevent mucositis has been well studied in randomized studies that show it is effective in a wide range of patients and approaches. Epstein and team's original research formed the basis for using benzydamine with evidence, showing markedly decreased mucositis in head and neck cancer patients treated with standard fractionated radiotherapy. The trial pointed out that benzydamine provides the most obvious benefits when radiation doses go over 25 Gray and continues to help protect even up to 50 Gray. More studies have added that people given chemoradiotherapy often have worse mucositis than those given either treatment alone. Patients undergoing radiation therapy take benzydamine hydrochloride oral rinse, diluted to 0.15% strength and use it as a mouthwash for sixty seconds about three to four times a day both while getting radio therapy and for several weeks after the treatment. Evidence from clinical trials indicates that giving benzydamine prophylactically, before the first radiation fraction, leads to better results than starting treatment once mucositis symptoms show up. It seems better to treat for an extra 2-4 weeks beyond radiotherapy to help repair tissue inside the mouth and prevent problems that develop after treatment. Include benzydamine in a full mucositis prevention plan and improvements are often seen in how much pain patients report, how they swallow and how they enjoy life(6). A number of studies have shown that benzydamine works just as well or better than other common oral treatments, including chlorhexidine,

povidone-iodine and a range of anesthetics and fewer patients complain of any problems with benzydamine. The benefits of benzydamine prophylaxis found in trials have been similarly observed in clinical practice. More people on benzydamine treatment needed fewer opioid drugs, required less nutrition support and interruptions to their care were seen less often. Trials have regularly found that the treatment is well tolerated, with most side effects being mild such as different taste and short-term numbness in the mouth that disappears after discontinuing the drug.

4.Comparison to Other Forms of Therapy

Approaches to mucositis prevention and treatment cover a wide variety of methods, ranging from simple mouth care to advanced photobiomodulation and each has its own way it works, level of effectiveness and considerations for practice. Benzydamine is favored over other options in international treatement guidelines and clinical practice recommendations, largely due to its numerous unique benefits, when compared to these other methods. While photobiomodulation therapy works equally well as benzydamine in preventing the worst cases of mucositis, its availability in clinics is often hindered by the need for special tools, knowledgeable staff and a lot of extra time. It is difficult for patients to manage daily short photobiomodulation sessions for their whole treatment when compared to how easy it is for them to use benzydamine mouthwash as needed. Research has shown that cryotherapy works best in chemotherapy regimens that have high-dose melphalan or 5-fluorouracil boluses and it doesn't help with radiation-induced mucositis, so its use is limited to those chemo protocols(7). Chemical modulators such as keratinocyte growth factor (palifermin) have helped in hematopoietic stem cell transplantation but are given systemically and can lead to potentially serious side effects, with costs that are much higher than benzydamine therapy applied just to the skin. Benzydamime, unlike chlorhexidine-containing mouthwash, can help prevent both secondary and primary mucositis. Many suggest natural products, especially those with honey, herbal components and probiotics, but most lack the robust findings to support their use, while benzydamine studies have shown stronger results and is more widely used. Even if they act as barriers, no treatments for chemical irritation target the main reason behind mucositis. Medical considerations support using benzydamine more than other drugs because it is inexpensive, easy to find and simple to provide which uses fewer healthcare resources. Adding benzydamine to basic dental care habits or nutritional plans has been proven to make treatment more successful, while at the same time keeping costs low and making the methods practical for use in clinics.

5.Knowing When a Medicine is Contraindicated and Side Effects

Over a long period, clinical use and constant safety monitoring have concluded that benzydamine hydrochloride is among the safest drugs that help prevent mucositis in patients with cancer. Minimal amounts of the drug are absorbed into the blood stream when used as prescribed for oral mucositis prevention. The local effect of this drug contributes to a very low chance of damaging the whole body, allowing it to be given to those considered most at risk by other drugs. The most typical side effects are mild and go away fast, often appearing as slight taste changes, oral tingling or numbness and sometimes a quick burning feeling that reduces when you use the product more often. Patients tend to handle these local effects well and they do not usually cause people to stop using the medication, since compliance remains over 90%. Only a very small number of people experience allergic reactions to benzydamine; those who do account for less than 0.1% of all treated patients. Allergic reactions usually come out as a sore or slightly swollen mouth, possibly a rash, that goes away as soon as you stop taking the medication. Because benzydamine is administered topically and absorbed systemically only to a small extent, it usually does not interact with other drugs used to treat cancer or as supportive care. Having studied pediatrics, pregnancy and various liver or kidney issues thoroughly, it has been proved that benzydamine is suitable for these populations. For most patients who need mucositis protection, benzydamine is safe to use because significant contraindications are rare, except for those hypersensitive to benzydamine or its similar chemicals. (Benzydamine use) results consistently show that patients prefer it over other interventions, are more satisfied and comfortable and are more likely to stick to their cancer care plans(8). No safety issues or toxicity effects have been found with long-term use of benzydamine, according to the safety data from patients taking repeated rounds of treatment or preventive drugs, making its use safe for these patients.

6.How Global Healthcare is Implemented and Accessed

Benzydamine therapy for preventing mucositis is being tried across the world, but there are many important differences in its use in different countries, due to variations in healthcare, finances and regulations. Because healthcare systems in many high-income countries are comprehensive, benzydamine can now be found in most cancer treatment protocols, thanks to its widespread insurance coverage and many awareness programs for healthcare professionals. Yet, most of the global cancer cases are now in low- and middle-income countries, where the high cost of care and shortages can keep useful treatments like benzydamine unaffordable. Because of this, benzydamine gaining a place on the WHO's Essential Medicines List is extremely important, but implementing this benefit will depend on teamwork among international organizations, manufacturers and healthcare authorities at the local level. Using special pricing methods to match what people in a region can afford can greatly help more people access these products and also support the business side of the industry. Generic formulation development has been very important for lowering prices, since numerous countries have successfully created local production strategies to maintain standards and reduce what people pay. With help from technology and capacity building measures, countries in the South could boost their manufacturing, use less imported goods and protect their supplies(9). The successful use of telehealth depends on training providers who are familiar with their cultures, speak their languages and have access to clinical systems. Data shows a combination of learning styles, cultural viewpoints and diverse healthcare seeking behaviors affect treatment outcomes, so these educational and awareness campaigns should address these. Telemedicine and digital platforms introduce new ways to help share essential knowledge and therapies with regions in need, while also allowing remote oversight. Together with scientists in different parts of the world, institutions can build evidence that is important locally and advance global scientific knowledge. To make sure that expanded access is safe, it's important to have quality assurance systems and regulations that work the same everywhere. Group efforts between government agencies, non-governmental organizations, universities and businesses could make it easier to solve barriers to implementation. Long-term success of global access initiatives depends on having health insurance expand, government funds be provided and support from donors.

7.The Connection between the Microbiome and Custom Medical Treatment

By exploring changes in the oral microbiome while a person receives cancer treatment, we now see that benzydamine therapy, the community of microbes and individual traits interact in many ways which can support developing personalized medicine for mucositis protection. Microbes living in the oral cavity number more than 700 and are balanced in their environment, but cancer treatments can drastically alter their types and functions, leading to mucositis. This substance has antimicrobial actions too which help it protect against microorganisms that harm the body but not against those that support a healthy mouth and immune system. Making use of metagenomic research, recent studies discovered that higher Gram-negative anaerobes and lower numbers of Lactobacillus and Streptococcus can increase a patient's likelihood of developing mucositis. The makeup of each person's microbiome which is affected by heredity, their diet, place of residence and antibiotic usage, results in unique risks that may help determine the best benzydamine course for each person. It has been demonstrated by pharmacomicrobiomics, a new field, that specific bacterial enzymes can process benzydamine, influencing the amount and effectiveness of the drug at the application site in people differently. Adding probiotics during cancer treatment to rebuild good bacteria populations might help preserve benzydamine's effect and treat the whole-body dysbiosis caused by cytotoxic medicines. Monitoring of the microbiome during treatment becomes possible thanks to 16S rRNA sequencing and whole-genome shotgun sequencing. Using microbiome information, clinical information and treatment results, machine learning systems are able to point out where individual responses to benzydamine therapy may not work and find patients who could benefit from combination or alternative therapies. Using microbiome information to guide dosing is a chance to improve effects, save money and avoid too much medication. Together, benzydamine and adjuvant microbiome therapies could provide whole protection for oral health. The speed with which the microbiome restores after treatment ends tells us the best approach to monitoring patients and determining the duration of treatment. Adding microbiome analysis to clinical trial design may speed up the development of new mucositis prevention methods that fit with the differences between individuals(10).

8.How the Economy Responds and Medical Care Use

The effects of benzydamine on reducing mucositis go beyond the drug's price and involve important effects on healthcare resources and the wider community which greatly benefit cancer patients and health systems. Detailed studies show that treating with benzydamine can greatly lessen expenses caused by later health care, including needing the emergency department less, visiting the hospital less and using fewer intensive treatments. The use of benzydamine therapy to stop severe mucositis leads to a clear drop in how much opioid pain medication patients use, this results in fewer problems linked to too much opioid use and less money being spent on managing pain issues. Mucositis prevention that contains benzydamine reduces the need for nutritional support which brings down costs and betters a patient's quality of life. When patients are treated with benzydamine, delay in treatment and dose reductions become rare, helping cancer treatment work for the patient over the long run. Improved productivity is achieved as nurses need less time to manage mucositis, less patient time spent with physicians for symptom control and fewer delays or complications during clinic visits. When mucositis is controlled, both patients' professional and personal losses are reduced, as well as any medical costs they might face, leading to greater economic growth. There is a wide variance in how insurance companies deal with paying for benzydamine; while some include it in their easy-to-access medicines, some require that doctors get permission before the patient may be prescribed it. It has consistently been discovered that benzydamine is less expensive and still works as well as the other interventions studied. Analyses of budget impacts for healthcare institutions indicate that introducing benzydamine can be either cost neutral or save money inside a few months, making it popular among systems on tight budgets. With mucositis prevention recognized as a key goal, there are now financial bonuses for doctors adding preventive strategies into their care plans such as using benzydamine therapy. Analysis of healthcare costs globally reveals that comparisons can be very different, depending on local conditions. Therefore, specific economic study is needed to guide policy decisions.

9.The Latest Developments in Medicine and How We Give Treatments

The combination of benzydamine therapy and modern drug technologies and methods is a fast-growing area that aims to increase treatment effectiveness, make therapy more convenient and expand the uses of the drug. With nanotechnology, researchers have designed nanoparticles that help benzydamine penetrate the tissues well, remain in the mouth longer and release the required amount for a longer time, so less has to be taken. Stable liposomal preparations have been reported to deliver drugs more effectively to cells while protecting them from side effects experienced by the body as a whole. Polymers in mucoadhesive delivery systems can bind to the mucous membranes in the mouth, helping the drug stay in contact longer and be released over an extended period, solving one of the problems found in regular mouthwash products. Sending medicines to a certain part of the body using pH or enzyme triggers could help provide treatment that adjusts to the inflammation found in mucositis. Thanks to three-dimensional printing, oral devices can now be made to release benzydamine in ways and shapes determined by each person's anatomy and the treatment they need. Combining hydrogel formulations with additional therapeutics allows them to tackle multiple elements of mucositis development together. Electrospun nanofiber systems open up new ways to make biodegradable films to treat oral ailments by giving off the drug for longer periods. Biocompatible polymer-based microencapsulation techniques help prevent drugs from breaking down and make it possible to control their release and how they are distributed. Using advanced formulation techniques has made it possible to develop preparations that overcome patients' taste issues which is critical for children and people with chemotherapy-related changes to taste. Using digital tools that involve packaging for monitoring treatment and mobile apps to guide patients could help people stick to their medications and make therapy updates immediately. Adding benzydamine to products that also include antimicrobial, analgesic or healing ingredients offers a chance to make treatment easier and more effective. Guidelines for new drug delivery systems provide both risks and rewards, so careful consideration of safety, effectiveness and manufacturing is necessary while dealing with tough approval procedures for advanced formulas.

10.Outcomes and Quality of Life: Patient Perspective

Examining the effects of benzydamine therapy on patient-centered outcomes and quality of life adds important detail to clinical assessment, since it extends past the usual measures of treatment success to reflect the whole

experience of patients living with cancer. Great improvements in quality of life domains are consistently reported when benzydamine is used together with current mucositis prevention treatment protocols among patients with head and neck cancer. Using standardized scales, patients treated with benzydamine before surgery report less intense pain as well as less burning, stabbing and breakthrough pain. Based on the use of both subjective and objective methods, swallowing assessments demonstrate that people in the benzydamine group have better swallowing and milder dysphagia than those without this treatment. Signs of good nutrition such as patients' weight, lower protein intake and nutritional biomarkers, show an improved trend in those using benzydamine, reflecting the drug's benefits to oral health and feeding. Maintained voice abilities and lower speech-related disability are detected during communication and speech quality assessments such information mattering to patients who require speaking for important daily tasks. Making sleep better, as measured with common testing tools, helps to limit the effect of pain on sleep and promotes more comfort while in treatment. Improved feelings of both anxiety and depression are linked to more confidence in treatment and fear of possible difficulties with treatment. People receiving effective mucositis prevention were back to their usual lives sooner and experienced less treatment-related disruption. When patients have fewer severe mucositis symptoms, assessing family and caregiver burden often finds that stress is lower and care requirements are milder, benefiting the patient's social and family life. Following up patients over time allows researchers to study how mucositis prevention can affect their oral health, quality of life and happiness with treatment for years to come. Assessment of quality of life in medicine should take into account differences in cultures, challenging languages and unique ways that people express their pain or disability. Integrating these measures helps clinicians assess treatments right away and customize care with attention to what matters most to each patient.

11.Evolution of policies related to anesthesia in healthcare settings

Benzydamine therapy for mucositis prevention is regulated differently as new science, changing medical methods and various approaches to drug and guideline development arise around the world. Discussions with the US Food and Drug Administration on benzydamine have covered efficacy, safety and need, while also discussing the best method to approve supportive care treatments for cancer. Data collected in clinical trials and real-life situations is highly valued by the European Medicines Agency, so new drugs are given conditional approval and continued scrutiny during use. The ways Health Canada regulates benzydamine were formed by considering what has happened internationally and by being relevant to those using the system and those being treated here. For benzydamine generics, governments encounter unique challenges since effectively demonstrating equivalence of topical products is not straightforward using standard pharmacokinetics. The ICH is one group working on worldwide harmonization, with the aim of aligning rules but still ensuring safety and effective results in many countries. When making clinical practice guidelines, professional organizations take in new scientific information, counsel from experts and practical steps to guide healthcare providers. The guidelines from MASCC/ISOO are considered the main reference for managing mucositis, due to frequent updates following new research and improvements in supportive cancer care. ASCO and ESMO, as recognized groups in the field, present suggestions for benzydamine administration that may be emphasized differently because of regional practices and medical systems. Pediatric cancer care needs special consideration for age-matched medicines, ways to give them safely and effectively and following safety guidelines that fit the needs of children being treated. Drugs containing benzydamine can qualify for orphan drug and rare-disease status which helps sponsors invest in research and development aimed at underserved groups. More evidence on the safety and continual effectiveness of benzydamine is still being gathered through post-marketing surveillance which helps regulators with ongoing decisions. With new ideas in regulatory science, it becomes possible to produce more valuable and informative evidence for rules and guidelines.

12.Conclusion and Future work

Among all available treatments, benzydamine hydrochloride has become a leading option in supporting cancer care, especially for patients with head and neck cancers experiencing unpleasant mouth side effects of radiation treatments. Because it works on inflammation, provides pain relief and shields tissue, while also being safe and easy to use, many doctors now recommend it in many countries. The ways in which benzydamine works on the body to

help heal inflammation are now being uncovered and it has been found that these processes make it unique among anti-inflammatory molecules and therefore important for fighting mucositis. Many controlled studies have shown that oral rinses help lower the severity of mouth and throat inflammation, make patients feel better, improve their life quality and enhance their ability to swallow, eat and communicate. Its economic benefits, including low expenses and lesser use of healthcare resources, allow benzydamine therapy to fit into regular cancer care and become available to more patients in hospitals. With cancer treatment changing due to new therapies, benzydamine is expected to be used more widely in supportive care as researchers study how it can be used in combination treatments, personalized medicine and many diverse treatment methods. In the future, better benzydamine formulations, more uses for cancer and improved ways of applying it may lead to even better results for people around the world affected by cancer. Experts see the work on benzydamine as important for making cancer treatments easier to manage and more understandable for people receiving cancer care.

Acknowledgement: Nil

Conflicts of interest

The authors have no conflicts of interest to declare

References

1. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs. 2004;20(1):30–35.
2. Kazemian A, Kamian S, Aghili M. Benzydamine mouthwash for prevention of radiation-induced oral mucositis. J Iran Med Sci. 2004;29(4):179–184.
3. Elad S, Cheng KKF, Lalla RV. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423–4431.
4. Dodd MJ, Miaskowski C, Greenspan D. Radiation-induced mucositis: a review of current management and new agents. Oncol Nurs Forum. 2000;27(4):633–640.
5. McGuire DB, Correa ME, Johnson J. Efficacy and safety of benzydamine oral rinse in prevention of chemoradiotherapy-induced oral mucositis. Support Care Cancer. 2006;14(5):428–432.
6. Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lontou A. Benzydamine for the prevention of radiation-induced oral mucositis in head and neck cancer patients. Support Care Cancer. 2011;19(8):1075–1084.
7. Epstein JB, Thariat J, Bensadoun RJ. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–422.
8. Lalla RV, Bowen J, Barasch A. MASCC/ISOO guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–1461.
9. Kazemian A, Kamian S, Aghili M. Benzydamine in prevention of radiation-induced oral mucositis: a randomized clinical trial. Med Oral Patol Oral Cir Bucal. 2008;13(10):E76–E79.
10. Kouloulias V, Tolia M, Gkioka E. Topical use of benzydamine hydrochloride for the prevention of radiation-induced mucositis: results from a prospective randomized clinical trial. Anticancer Res. 2017;37(2):1015–1020.